Evidence map›Paper›PMID 38700023›Full record

ArticleActa obstetricia et gynecologica Scandinavica2024

Maternal opioid use during pregnancy and the risk of neonatal opioid withdrawal syndrome in the offspring.

Anna Warncke Kristensen, Vibeke Vestermark, Anette Kjærbye-Thygesen, Maria-Christina Eckhardt, Ulrik Schiøler Kesmodel

Abstract readMulticenter Study
In one paragraph

Article in Acta obstetricia et gynecologica Scandinavica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anna Warncke KristensenDepartment of Obstetrics and Gynecology, Naestved, Slagelse, Ringsted Hospitals, Slagelse, Denmark.ORCID 0009-0005-9540-2436
Vibeke VestermarkDepartment of Obstetrics and Gynecology, Naestved, Slagelse, Ringsted Hospitals, Slagelse, Denmark.
Anette Kjærbye-ThygesenDepartment of Obstetrics and Gynecology, Copenhagen University Hospital, Hvidovre, Denmark.
Maria-Christina EckhardtHans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
Ulrik Schiøler KesmodelDepartment of Obstetrics and Gynecology, Aalborg University Hospital, Aalborg, Denmark.ORCID 0000-0003-3868-106X

Funding

Naestved, Slagelse, and Ringsted Hospitals' Research Fund
6 · The paper itself

Abstract

introductionNeonatal opioid withdrawal syndrome (NOWS) is caused by sudden cessation from in utero exposure to opioids. The indications for opioid use during pregnancy are diverse including medication for opioid use disorder and analgesia. The opioid dose typically depends on the indication, with higher doses used for medication for opioid use disorder and lower doses used for analgesia. The aim of this study was to investigate the relationship between maternal opioid dose during pregnancy and the risk of NOWS. MATERIAL AND

methodsWe conducted a historical multicenter cohort study of neonates prenatally exposed to opioids in Eastern Denmark during a six-year period from 2013 to 2018. The data was extracted from reviewing the individual's medical record(s), which were identified through a search of the Danish National Patient Register. Four groups (quartiles) according to maternal opioid dose during the last four weeks prior to delivery were compared. Unadjusted and adjusted logistic regression analyses were conducted to examine the risk of NOWS while controlling for relevant covariates.

resultsA total of 130 in utero opioid exposed neonates were included. The majority of the pregnant patients (88%) were treated with opioids for analgesic purposes. Overall, 52% of neonates developed NOWS. The cumulative incidence of NOWS was 21%, 28%, 67% and 91% at maternal average daily dose of morphine milligram equivalent during the last four weeks prior to delivery of 0.7-14 (group I), 14.3-38.6 (group II), 40-90 (group III) and 90.9-1440 (group IV), respectively. Compared to group I the adjusted odds (aOR) of NOWS increased significantly in group III (aOR 10.6 [2.9-39.1]) and group IV (aOR 37.8 [7.6-188.2]) but not in group II (aOR 1.5 [0.4-5.2]). No cases of NOWS were reported at maternal dose less than an average daily dose of five morphine milligram equivalent during the last four weeks prior to delivery. No significant changes in the incidence of NOWS were observed between 2013 and 2018.

conclusionsThe odds of neonatal opioid withdrawal syndrome increased significantly as the maternal average daily dose of morphine milligram equivalent during the last four weeks prior to delivery surpassed 40.

Indexed as

Analgesics, OpioidNeonatal Abstinence SyndromeOpioid-Related DisordersPregnancy ComplicationsPrenatal Exposure Delayed EffectsAdultCohort StudiesDenmarkFemaleHumansInfant, NewbornMalePregnancyAnalgesics, Opioidmethadoneneonatal abstinence syndromeneonatal withdrawal syndromeopioidopioid analgesicspregnancy

Identifiers

PMID38700023
PMCPMC11266641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.